Patients with Malignant Pleural Mesothelioma
A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumour-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma.
ClinicalTrials.gov Identifier: NCT01721018
Principal Investigators: Prof Penella J Woll, Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, S10 2SJ, UK and Dr Kevin Blyth Consultant Respiratory Physician, Queen Elizabeth University Hospital, Glasgow, G51 4TF
This study has now reached its recruitment target and is closed to new participants.
Younger Patients with Non-Central Nervous System (Non-CNS) Solid Tumors
A Phase I Dose Escalation Study of Intratumoral and Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors
ClinicalTrials.gov Identifier: NCT00931931
Principal Investigator: Timothy Cripe, M.D., PhD. Nationwide Children's Hospital
This study is currently recruiting participants at Nationwide Children’s Hospital, Columbus, Ohio in respect of the intravenous administration of SEPREHVIR. The study has completed recruitment of patients receiving intratumoral administration.
CLINICAL STUDIES - RECRUITMENT COMPLETED
High Grade Glioma
Three Phase 1 Studies to evaluate the safety and tolerability of SEPREHVIR in adult patients with primary or recurrent malignant glioma. SEPREHVIR was administered intratumourally (with and without subsequent resection) and into the brain surrounding tumour.
Head & Neck Cancer
Phase 1 study of a single preoperative intratumoural injection of SEPREHVIR in patients with resectable squamous cell carcinoma of the head and neck.
Phase 1 study of single and multiple intratumoural administrations of SEPREHVIR in patients with metastatic melanoma.